Vistin Pharma ASALTS:0RAM 77 3-Year EBITDA Growth Rate is 142.60% as of Mar. 2026, which is 2902% above its 10-year median of 4.75. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.69 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 813 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 99.14% on this metric.
During the past 12 months, Vistin Pharma ASA's average EBITDA Per Share Growth Rate was 1.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 142.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vistin Pharma ASA was 142.60% per year. The lowest was -55.10% per year. And the median was 4.75% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Vistin Pharma ASA 3-Year EBITDA Growth Rate Related Terms
LTS:0RAM vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 142.60% mean?
Vistin Pharma ASA (LTS:0RAM) has a 3-Year EBITDA Growth Rate of 142.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vistin Pharma ASA and its competitors. This is 2902% above median its historical median of 4.75. According to the industry distribution chart, Vistin Pharma ASA ranks #7 out of 813 companies in the Drug Manufacturers industry, placing it in the top 0.90000000000001%.
Is Vistin Pharma ASA's 3-Year EBITDA Growth Rate too high?
Vistin Pharma ASA's current 3-Year EBITDA Growth Rate of 142.60% is 2902% above median its 10-year median of 4.75. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Vistin Pharma ASA's value of 142.60% is 1502.2% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #7 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #7 out of 813 companies for 3-Year EBITDA Growth Rate. This places Vistin Pharma ASA in the top 1% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Vistin Pharma ASA's value of 142.60% is 1502.2% above this benchmark. While the company's 10-year median is 4.75 vs. the industry median of 8.90, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current 3-Year EBITDA Growth Rate of 142.60% is 1502.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current 3-Year EBITDA Growth Rate is 142.60%, which is 2902% above median its own 10-year median of 4.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.69, compared to a current price of kr20.30 — trading 21% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 142.60%, which is 2902% above median its 10-year median of 4.75 and 1502.2% above the Drug Manufacturers industry median of 8.90. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current 3-Year EBITDA Growth Rate is 142.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.30 is trading 21% below its estimated GF Value™ of kr25.69.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
3-Year EBITDA Growth Rate: 142.60% (2902% above median its 10-year median of 4.75)
GF Value™: kr25.69 vs. price of kr20.30 (21% below fair value)
Industry Position: 1502.2% above the Drug Manufacturers median (#7 of 813)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 